Skip to main content
Erschienen in: Hepatology International 3/2019

11.04.2019 | Original Article

A proposed pathologic sub-classification of drug-induced liver injury

verfasst von: Tailing Wang, Xinyan Zhao, Chen Shao, Lihong Ye, Jing Guo, Na Peng, Honglei Zhang, Jian Li, Yuanyuan Kong, Hong You, Jidong Jia

Erschienen in: Hepatology International | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of this study was to establish a new pathologic sub-classification of drug-induced liver injury (DILI) in combination with serum chemistry parameters and clinical observations.

Methods

From 777 DILI cases diagnosed in China–Japan Friendship Hospital from 2003 to 2014, 590 cases without other concomitant liver diseases were selected for the study. Pathological classification was established. Pathology and serum biochemical correlation analyses in 208 acute cases with complete biochemical data and prognostic information were conducted.

Results

We established a pathological classification of DILI according to the target cells of the liver (hepatocytes, bile duct epithelial cells, liver vascular and sinusoidal endothelial cells). In the 590 cases of DILI analyzed, hepatocyte injury accounted for 67.0%, bile duct epithelial injury (including cholestasis and mixed type of injury) 23.9%, and vascular injury 8.8%; about half of them were caused by the administration of traditional Chinese herbal medicines. Acute hepatocyte injury (lobular hepatitis) is further divided into mild, moderate and severe subtypes, while the mixed type of injury is categorized as cholestatic hepatitis and mixed hepatitis. The dynamic liver enzyme curves were established between lobular hepatitis and mixed-type hepatitis based on the combined consideration of histopathology and serum chemistry data. We proved that R value > 5 with cholestasis is a special feature of mixed hepatitis, which clarified the suspicion of the previous clinical classification of R value. Greater attention should be paid to drug-induced bile duct vanishing syndrome and drug-induced vascular injury.

Conclusion

The pathological classification is simple to adopt and practically useful, which demonstrates the consistency between clinical features and liver pathology. The correlation between pathology and clinical biochemistry is an important way to acquire further understanding of DILI.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Bjornsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis 2014;34(2):115–122CrossRefPubMed Bjornsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis 2014;34(2):115–122CrossRefPubMed
3.
Zurück zum Zitat Teng GJ, Li BS, Zhao J, et al. Characteristics and trends of patients with drug-induced liver injury during the last ten years in China: a single-center experience. Chin Hepatol 2014;19(5):329–331 Teng GJ, Li BS, Zhao J, et al. Characteristics and trends of patients with drug-induced liver injury during the last ten years in China: a single-center experience. Chin Hepatol 2014;19(5):329–331
4.
Zurück zum Zitat Shen T, Duan ZJ, Zhuang H. The epidemiology of drug-induced liver injury. Chin Hepatol 2015;20(10):19–23 Shen T, Duan ZJ, Zhuang H. The epidemiology of drug-induced liver injury. Chin Hepatol 2015;20(10):19–23
6.
Zurück zum Zitat Hu XQ. Discussion on pathological scoring system of drug-induced liver injury. Chin J Hepatol 2012;20(3):176–177 Hu XQ. Discussion on pathological scoring system of drug-induced liver injury. Chin J Hepatol 2012;20(3):176–177
7.
Zurück zum Zitat Teschke R, Larrey D, Melchart D, Danan G. Traditional Chinese Medicine (TCM) and herbal hepatotoxicity: RUCAM and the role of novel diagnostic biomarkers such as microRNAs. Medicines 2016;3(3):E18CrossRefPubMed Teschke R, Larrey D, Melchart D, Danan G. Traditional Chinese Medicine (TCM) and herbal hepatotoxicity: RUCAM and the role of novel diagnostic biomarkers such as microRNAs. Medicines 2016;3(3):E18CrossRefPubMed
8.
Zurück zum Zitat Danan G, Teschke R. Drug-induced liver injury: why is the Roussel Uclaf causality assessment method (RUCAM) still used 25 years after its launch? Drug Saf 2018;41(8):735–743CrossRef Danan G, Teschke R. Drug-induced liver injury: why is the Roussel Uclaf causality assessment method (RUCAM) still used 25 years after its launch? Drug Saf 2018;41(8):735–743CrossRef
9.
Zurück zum Zitat Branch of Infectious Diseases and Parasites of Chinese Medical Association, Branch of Liver of Chinese Medical Association. Prevention and treatment of viral hepatitis. Chin J Hepatol 2000;8(6):324–329 Branch of Infectious Diseases and Parasites of Chinese Medical Association, Branch of Liver of Chinese Medical Association. Prevention and treatment of viral hepatitis. Chin J Hepatol 2000;8(6):324–329
10.
Zurück zum Zitat Popper H, Rubin E, Cardiol D, Schaffner F, Paronetto F. Drug-induced liver disease: a penalty for progress. Arch Intern Med 1965;115:128–136CrossRefPubMed Popper H, Rubin E, Cardiol D, Schaffner F, Paronetto F. Drug-induced liver disease: a penalty for progress. Arch Intern Med 1965;115:128–136CrossRefPubMed
11.
12.
Zurück zum Zitat Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11(2):272–276CrossRefPubMed Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11(2):272–276CrossRefPubMed
13.
Zurück zum Zitat Zimmerman HJIK. Hepatic injury due to drugs and toxins. Pathology of the liver 4th ed. Edinburgh: Churchill Liveingstone; 2002. 621–710 Zimmerman HJIK. Hepatic injury due to drugs and toxins. Pathology of the liver 4th ed. Edinburgh: Churchill Liveingstone; 2002. 621–710
14.
Zurück zum Zitat Kleiner DE. The histopathological evaluation of drug-induced liver injury. Histopathology 2017;70(1):81–93CrossRefPubMed Kleiner DE. The histopathological evaluation of drug-induced liver injury. Histopathology 2017;70(1):81–93CrossRefPubMed
15.
Zurück zum Zitat Robles-Diaz M, Lucena MI, Kaplowitz N, et al. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 2014;147(1):109 e105–118 e105CrossRef Robles-Diaz M, Lucena MI, Kaplowitz N, et al. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 2014;147(1):109 e105–118 e105CrossRef
17.
Zurück zum Zitat Desmet VJ. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol 1997;26(Suppl 1):31–35CrossRefPubMed Desmet VJ. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol 1997;26(Suppl 1):31–35CrossRefPubMed
18.
Zurück zum Zitat DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002;22(1):27–42CrossRefPubMed DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002;22(1):27–42CrossRefPubMed
19.
Zurück zum Zitat Nakanuma Y, Tsuneyama K, Ohbu M, Katayanagi K. Pathology and pathogenesis of idiopathic portal hypertension with an emphasis on the liver. Pathol Res Pract 2001;197(2):65–76CrossRefPubMed Nakanuma Y, Tsuneyama K, Ohbu M, Katayanagi K. Pathology and pathogenesis of idiopathic portal hypertension with an emphasis on the liver. Pathol Res Pract 2001;197(2):65–76CrossRefPubMed
20.
Zurück zum Zitat Liu X, Wang TL, Xiang CH, et al. Liver pathology in idiopathic portal hypertension. Chin J Hepatol 2007;15(5):374–377 Liu X, Wang TL, Xiang CH, et al. Liver pathology in idiopathic portal hypertension. Chin J Hepatol 2007;15(5):374–377
21.
Zurück zum Zitat Gao H, Li N, Wang JY, et al. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids [Journal Article]. J Dig Dis 2012;13(1):33–39CrossRefPubMed Gao H, Li N, Wang JY, et al. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids [Journal Article]. J Dig Dis 2012;13(1):33–39CrossRefPubMed
22.
Zurück zum Zitat Bjornsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports. Hepatology 2016;63(2):590–603CrossRefPubMed Bjornsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports. Hepatology 2016;63(2):590–603CrossRefPubMed
23.
Zurück zum Zitat Ren ZQ, Wang JH, Guo XY, et al. A review analysis of chinese literatures 2005–2014: clinical features of drug-induced liver injury. Chin J Pharmacoepidemiol 2016;0(5):284–289 Ren ZQ, Wang JH, Guo XY, et al. A review analysis of chinese literatures 2005–2014: clinical features of drug-induced liver injury. Chin J Pharmacoepidemiol 2016;0(5):284–289
24.
Zurück zum Zitat Wang G-Q, Deng Y-Q, Hou F-Q. Overview of drug-induced liver injury in China. Clin Liver Dis 2014;4(1):26–29CrossRef Wang G-Q, Deng Y-Q, Hou F-Q. Overview of drug-induced liver injury in China. Clin Liver Dis 2014;4(1):26–29CrossRef
Metadaten
Titel
A proposed pathologic sub-classification of drug-induced liver injury
verfasst von
Tailing Wang
Xinyan Zhao
Chen Shao
Lihong Ye
Jing Guo
Na Peng
Honglei Zhang
Jian Li
Yuanyuan Kong
Hong You
Jidong Jia
Publikationsdatum
11.04.2019
Verlag
Springer India
Erschienen in
Hepatology International / Ausgabe 3/2019
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-019-09940-9

Weitere Artikel der Ausgabe 3/2019

Hepatology International 3/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.